Generating Anti-CD19 CAR T Cells with High Efficiency and Viability via mRNA Electroporation

Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary and promising approach for cancer treatment. However, its potential is limited by technical challenges and safety risks associated with viral transduction–based CAR T-cell generation workflows. Nonviral methods, such as electroporation, represent a potentially safer and less challenging approach for generating CAR T cells. Flexible, high throughput technologies such as flow cytometry can greatly assist in reducing the challenges of CAR-T workflows.

In this webinar, we describe the generation of anti-CD19 CAR T cells in an mRNA electroporation–based CAR T-cell workflow optimized for efficiency and viability. See how CAR transfection efficiencies as high as ~70 and ~90% in primary and immortalized human T cells, respectively, and a viability of ~60% in primary human T cells, were achieved. These data highlight the utility of the Gene Pulser Xcell Electroporation System for generating CAR T cells via mRNA electroporation and the ZE5 Cell Analyzer for expression and analysis.